These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11075806)

  • 21. Oxidative stress regulates type 3 deiodinase and type 2 deiodinase in cultured rat astrocytes.
    Lamirand A; Pallud-Mothré S; Ramaugé M; Pierre M; Courtin F
    Endocrinology; 2008 Jul; 149(7):3713-21. PubMed ID: 18420745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.
    Wilkinson KD
    Semin Cell Dev Biol; 2000 Jun; 11(3):141-8. PubMed ID: 10906270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel mechanism for the inhibition of type 2 iodothyronine deiodinase by tumor necrosis factor α: involvement of proteasomal degradation.
    Ogiwara T; Araki O; Morimura T; Tsunekawa K; Mori M; Murakami M
    Endocr J; 2013; 60(9):1035-45. PubMed ID: 23719846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type 2 iodothyronine deiodinase is highly expressed in human thyroid.
    Salvatore D; Tu H; Harney JW; Larsen PR
    J Clin Invest; 1996 Aug; 98(4):962-8. PubMed ID: 8770868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kip1 degradation via the ubiquitin-proteasome pathway.
    Tam SW; Theodoras AM; Pagano M
    Leukemia; 1997 Apr; 11 Suppl 3():363-6. PubMed ID: 9209391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of metamorphosis and the onset of the negative feedback loop between the thyroid gland and the pituitary is controlled by type II iodothyronine deiodinase in Xenopus laevis.
    Huang H; Cai L; Remo BF; Brown DD
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7348-53. PubMed ID: 11404476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degradation of subunits of the Sec61p complex, an integral component of the ER membrane, by the ubiquitin-proteasome pathway.
    Biederer T; Volkwein C; Sommer T
    EMBO J; 1996 May; 15(9):2069-76. PubMed ID: 8641272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ubiquitin-proteasome pathway: on protein death and cell life.
    Ciechanover A
    EMBO J; 1998 Dec; 17(24):7151-60. PubMed ID: 9857172
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies of the hormonal regulation of type 2 5'-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcription-polymerase chain reaction.
    Kim SW; Harney JW; Larsen PR
    Endocrinology; 1998 Dec; 139(12):4895-905. PubMed ID: 9832426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Cue1p in ubiquitination and degradation at the ER surface.
    Biederer T; Volkwein C; Sommer T
    Science; 1997 Dec; 278(5344):1806-9. PubMed ID: 9388185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sec61p-independent degradation of the tail-anchored ER membrane protein Ubc6p.
    Walter J; Urban J; Volkwein C; Sommer T
    EMBO J; 2001 Jun; 20(12):3124-31. PubMed ID: 11406589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein.
    Mayer TU; Braun T; Jentsch S
    EMBO J; 1998 Jun; 17(12):3251-7. PubMed ID: 9628862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 2 Iodothyronine Deiodinase Activity Is Required for Rapid Stimulation of PI3K by Thyroxine in Human Umbilical Vein Endothelial Cells.
    Aoki T; Tsunekawa K; Araki O; Ogiwara T; Nara M; Sumino H; Kimura T; Murakami M
    Endocrinology; 2015 Nov; 156(11):4312-24. PubMed ID: 26284425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ubiquitin-dependent protein degradation.
    Hochstrasser M
    Annu Rev Genet; 1996; 30():405-39. PubMed ID: 8982460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of selenocysteine 133 in catalysis by the human type 2 iodothyronine deiodinase.
    Buettner C; Harney JW; Larsen PR
    Endocrinology; 2000 Dec; 141(12):4606-12. PubMed ID: 11108274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The type II deiodinase is retrotranslocated to the cytoplasm and proteasomes via p97/Atx3 complex.
    Arrojo E Drigo R; Egri P; Jo S; Gereben B; Bianco AC
    Mol Endocrinol; 2013 Dec; 27(12):2105-15. PubMed ID: 24196352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4.
    Schneider MJ; Fiering SN; Pallud SE; Parlow AF; St Germain DL; Galton VA
    Mol Endocrinol; 2001 Dec; 15(12):2137-48. PubMed ID: 11731615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ubiquitin and the control of protein fate in the secretory and endocytic pathways.
    Bonifacino JS; Weissman AM
    Annu Rev Cell Dev Biol; 1998; 14():19-57. PubMed ID: 9891777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms.
    Burmeister LA; Pachucki J; St Germain DL
    Endocrinology; 1997 Dec; 138(12):5231-7. PubMed ID: 9389506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ER protein quality control and proteasome-mediated protein degradation.
    Brodsky JL; McCracken AA
    Semin Cell Dev Biol; 1999 Oct; 10(5):507-13. PubMed ID: 10597633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.